PURPOSE: NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802. METHODS: IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates. RESULTS: Of the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup. CONCLUSION: This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
PURPOSE: NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802. METHODS: IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates. RESULTS: Of the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup. CONCLUSION: This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
Authors: Erica H Bell; Peixin Zhang; Barbara J Fisher; David R Macdonald; Joseph P McElroy; Glenn J Lesser; Jessica Fleming; Arup R Chakraborty; Ziyan Liu; Aline P Becker; Denise Fabian; Kenneth D Aldape; Lynn S Ashby; Maria Werner-Wasik; Eleanor M Walker; Jean-Paul Bahary; Young Kwok; H Michael Yu; Nadia N Laack; Christopher J Schultz; Heidi J Gray; H Ian Robins; Minesh P Mehta; Arnab Chakravarti Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: David Capper; Hanswalter Zentgraf; Jörg Balss; Christian Hartmann; Andreas von Deimling Journal: Acta Neuropathol Date: 2009-10-02 Impact factor: 17.088
Authors: Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245
Authors: Pierre Bady; Davide Sciuscio; Annie-Claire Diserens; Jocelyne Bloch; Martin J van den Bent; Christine Marosi; Pierre-Yves Dietrich; Michael Weller; Luigi Mariani; Frank L Heppner; David R Mcdonald; Denis Lacombe; Roger Stupp; Mauro Delorenzi; Monika E Hegi Journal: Acta Neuropathol Date: 2012-07-19 Impact factor: 17.088
Authors: Benedikt Wiestler; David Capper; Tim Holland-Letz; Andrey Korshunov; Andreas von Deimling; Stefan Michael Pfister; Michael Platten; Michael Weller; Wolfgang Wick Journal: Acta Neuropathol Date: 2013-08-01 Impact factor: 17.088
Authors: J Gregory Cairncross; Meihua Wang; Robert B Jenkins; Edward G Shaw; Caterina Giannini; David G Brachman; Jan C Buckner; Karen L Fink; Luis Souhami; Normand J Laperriere; Jason T Huse; Minesh P Mehta; Walter J Curran Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Maarten M J Wijnenga; Pim J French; Hendrikus J Dubbink; Winand N M Dinjens; Peggy N Atmodimedjo; Johan M Kros; Marion Smits; Renske Gahrmann; Geert-Jan Rutten; Jeroen B Verheul; Ruth Fleischeuer; Clemens M F Dirven; Arnaud J P E Vincent; Martin J van den Bent Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300
Authors: Deborah Y Park; Martin C Tom; Yanwen Chen; Surabhi Tewari; Manmeet S Ahluwalia; Jennifer S Yu; Samuel T Chao; John H Suh; David M Peereboom; Glen H J Stevens; Gene H Barnett; Lilyana Angelov; Alireza Mohammadi; Thomas Hogan; Courtney Kissel; Brittany Lapin; Isabel Schuermeyer; Michael W Parsons; Richard Naugle; Erin S Murphy Journal: J Neurooncol Date: 2022-04-29 Impact factor: 4.130
Authors: Andrew B Lassman; Khê Hoang-Xuan; Mei-Yin C Polley; Alba A Brandes; J Gregory Cairncross; Johan M Kros; Lynn S Ashby; Martin J B Taphoorn; Luis Souhami; Winand N M Dinjens; Nadia N Laack; Mathilde C M Kouwenhoven; Karen L Fink; Pim J French; David R Macdonald; Denis Lacombe; Minhee Won; Thierry Gorlia; Minesh P Mehta; Martin J van den Bent Journal: J Clin Oncol Date: 2022-06-22 Impact factor: 50.717
Authors: Jessica L Fleming; Stephanie L Pugh; Barbara J Fisher; Glenn J Lesser; David R Macdonald; Erica H Bell; Joseph P McElroy; Aline P Becker; Cynthia D Timmers; Kenneth D Aldape; C Leland Rogers; Thomas J Doyle; Maria Werner-Wasik; Jean-Paul Bahary; Hsiang-Hsuan Michael Yu; David P D'Souza; Nadia N Laack; Penny K Sneed; Young Kwok; Minhee Won; Minesh P Mehta; Arnab Chakravarti Journal: JCO Precis Oncol Date: 2021-09-01
Authors: Yao Yu; Javier Villanueva-Meyer; Matthew R Grimmer; Stephanie Hilz; David A Solomon; Serah Choi; Michael Wahl; Tali Mazor; Chibo Hong; Anny Shai; Joanna J Phillips; Bruce H Wainer; Michael McDermott; Daphne Haas-Kogan; Jennie W Taylor; Nicholas Butowski; Jennifer L Clarke; Mitchel S Berger; Annette M Molinaro; Susan M Chang; Joseph F Costello; Nancy Ann Oberheim Bush Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029